Significant reduction in 6-year fragility fracture risk with zoledronate vs placebo for osteopenia
How to Cite
OrthoEvidence. Significant reduction in 6-year fragility fracture risk with zoledronate vs placebo for osteopenia. ACE Report. 2019;8(4):17. Available from: https://myorthoevidene.com/AceReport/Report/11001
Fracture Prevention with Zoledronate in Older Women with OsteopeniaN Engl J Med. 2018 Dec 20;379(25):2407-2416. doi: 10.1056/NEJMoa1808082
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
2000 postmenopausal women with osteopenia were randomized to treatment with infusion of either zoledronate 5mg or placebo every 18 months for 6 years. Participants were assessed for incidence of fractures, prespecified adverse events including mortality, vascular events, cancer, and osteonecrosis of the jaw, and bone mineral density after 6 years. Results demonstrated significantly lower incidence...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE